CytRx Corporation (CYTR) Stock Ratings


View Stock Quote:

Login Required

You must login before you can rate this stock.

Login Now

Community Rating:


Not Rated

No Current Ratings
View All-Time Ratings

Do the wall street analysts agree?

Consensus Recommendation:

View detailed analyst research

Other Member Ratings

View Most Rated Stocks

Member Call Date Rated Timeframe Start Price End Price Stock Gain/Loss Score Status
BadRecall BadRecall 04/19/2016 3 months $3.20 $0.63 -80.31% -80 Ended
Comments: Aldoxorubicin is modified doxorubicin (in use). No bad surprises in PII is the road to success.
Netteligent Netteligent 01/19/2015 1 week $3.32 $2.77 -16.57% 16 Ended
Comments:
B1capital B1capital 06/10/2014 3 months $4.73 $3.44 -27.27% -27 Ended
Comments:
BioPedro8 BioPedro8 01/02/2014 1 month $7.27 $6.94 -4.54% 4 Ended
Comments: Overbought. Hey, we're talking about phase II trial, not late stage pIII
fivetymes fivetymes 12/13/2013 3 months $5.99 $4.78 -20.13% -20 Ended
Comments: Review the ownership...
prometheusX prometheusX 12/11/2013 3 months $2.39 $5.10 +113.39% 113 Ended
Comments: Good news are imminent - recent sell-off due to irrational fear
oblo oblo 06/22/2011 1 Year $0.78 $4.88 +522.53% 522 Ended
Comments: Projecting strong long-term growth

Neither The NASDAQ OMX Group, Inc. nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investment related advice and comments are solely those of the individuals who publish them and do not in any way represent the opinions of NASDAQ OMX. Investors should undertake their own due diligence and carefully evaluate companies before investing.